Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8421-8432

  Awasthi, Sita ^a   Huang, Jialing ^a   Shaw, Carolyn ^a   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN C2; GLYCOPROTEIN D2; GLYCOPROTEIN E2; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DISEASE TRANSMISSION; DORSAL ROOT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE DOSAGE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE EVASION; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; IMMUNE EVASION; MICE; MICE, INBRED BALB C; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 84903901521     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01130-14     Document Type: Article

References (57)

1. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43. http://dx.doi.org/10.1056/NEJMoa1103151.
2. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661. http://dx.doi.org/10.1056/NEJMoa011915.
3. Wang F, Zumbrun EE, Huang J, Si H, Makaroun L, Friedman HM. 2010. Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons. Virology 405:269-279. http://dx.doi.org/10.1016/j.virol.2010.06.006.
4. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. 2012. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J. Virol. 86: 4586-4598. http://dx.doi.org/10.1128/JVI.07203-11.
5. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 200:1088-1095. http://dx.doi.org/10.1086/605645.
6. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. 2011. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6:e17748. http://dx.doi.org/10.1371/journal.pone.0017748.
7. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F. 2011. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J. Virol. 85:5036-5047. http://dx.doi.org/10.1128/JVI.02548-10.
8. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. 2012. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J. Gen. Virol. 93:1305-1315. http://dx.doi.org/10.1099/vir.0.040055-0.
9. Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K. 2011. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 29:1090-1098. http://dx.doi.org/10.1016/j.vaccine.2010.11.076.
10. Morello CS, Levinson MS, Kraynyak KA, Spector DH. 2011. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J. Virol. 85:3461-3472. http://dx.doi.org/10.1128/JVI.02521-10.
11. Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. 2012. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 30:6541-6550. http://dx.doi.org/10.1016/j.vaccine.2012.08.049.
12. Lachmann PJ, Davies A. 1997. Complement and immunity to viruses. Immunol. Rev. 159:69-77. http://dx.doi.org/10.1111/j.1600-065X.1997.tb01007.x.
13. Friedman HM, Wang L, Pangburn MK, Lambris JD, Lubinski J. 2000. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J. Immunol. 165:4528-4536. http://dx.doi.org/10.4049/jimmunol.165.8.4528.
14. Carroll MC. 2004. The complement system in B cell regulation. Mol. Immunol. 41:141-146. http://dx.doi.org/10.1016/j.molimm.2004.03.017.
15. Carroll MC. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986. http://dx.doi.org/10.1038/ni1113.
16. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. 1986. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J. Immunol. 137:1636-1641.
17. Harris SL, Frank I, Yee A, Cohen GH, Eisenberg RJ, Friedman HM. 1990. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J. Infect. Dis. 162:331-337. http://dx.doi.org/10.1093/infdis/162.2.331.
18. Hung SL, Peng C, Kostavasili I, Friedman HM, Lambris JD, Eisenberg RJ, Cohen GH. 1994. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 203:299-312. http://dx.doi.org/10.1006/viro.1994.1488.
19. Kostavasili I, Sahu A, Friedman HM, Eisenberg RJ, Cohen GH, Lambris JD. 1997. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 158:1763-1771.
20. Friedman HM. 2000. Immunologic strategies for herpes vaccination. JAMA 283:746. http://dx.doi.org/10.1001/jama.283.6.741.
21. Lubinski J, Wang L, Mastellos D, Sahu A, Lambris JD, Friedman HM. 1999. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190:1637-1646. http://dx.doi.org/10.1084/jem.190.11.1637.
22. Para MF, Goldstein L, Spear PG. 1982. Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J. Virol. 41:137-144.
23. Harandi AM. 2004. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J. Clin. Virol. 30:207-210. http://dx.doi.org/10.1016/j.jcv.2004.03.001.
24. Frank I, Friedman HM. 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol. 63:4479-4488.
25. Dubin G, Socolof E, Frank I, Friedman HM. 1991. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65:7046-7050.
26. Nagashunmugam T, Lubinski J, Wang L, Goldstein LT, Weeks BS, Sundaresan P, Kang EH, Dubin G, Friedman HM. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72:5351-5359.
27. Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM. 2011. The herpes simplex virus 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol. 85:3239-3249. http://dx.doi.org/10.1128/JVI.02509-10.
28. Judson KA, Lubinski JM, Jiang M, Chang Y, Eisenberg RJ, Cohen GH, Friedman HM. 2003. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J. Virol. 77: 12639-12645. http://dx.doi.org/10.1128/JVI.77.23.12639-12645.2003.
29. Awasthi S, Lubinski JM, Friedman HM. 2009. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 27:6845-6853. http://dx.doi.org/10.1016/j.vaccine.2009.09.017.
30. Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. 2011. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J. Virol. 85:10472-10486. http://dx.doi.org/10.1128/JVI.00849-11.
31. Bernstein DI, Earwood JD, Bravo FJ, Cohen GH, Eisenberg RJ, Clark JR, Fairman J, Cardin RD. 2011. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 29:2071-2078. http://dx.doi.org/10.1016/j.vaccine.2011.01.005.
32. Plotkin SA. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-409. http://dx.doi.org/10.1086/589862.
33. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD. 2014. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J. Infect. Dis. 209:828-836. http://dx.doi.org/10.1093/infdis/jit651.
34. Hook LM, Lubinski JM, Jiang M, Pangburn MK, Friedman HM. 2006. Herpes simplex virus type 1 and 2 glycoprotein C prevents complementmediated neutralization induced by natural immunoglobulin M antibody. J. Virol. 80:4038-4046. http://dx.doi.org/10.1128/JVI.80.8.4038-4046.2006.
35. McGraw HM, Friedman HM. 2009. Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites. J. Virol. 83:4791-4799. http://dx.doi.org/10.1128/JVI.02341-08.
36. Tal-Singer R, Peng C, Ponce De Leon M, Abrams WR, Banfield BW, Tufaro F, Cohen GH, Eisenberg RJ. 1995. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J. Virol. 69:4471-4483.
37. Hung SL, Srinivasan S, Friedman HM, Eisenberg RJ, Cohen GH. 1992. Structural basis of C3b binding by glycoprotein C of herpes simplex virus. J. Virol. 66:4013-4027.
38. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. 2006. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80:5283-5291. http://dx.doi.org/10.1128/JVI.02013-05.
39. Lin X, Lubinski JM, Friedman HM. 2004. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 78:2562-2571. http://dx.doi.org/10.1128/JVI.78.5.2562-2571.2004.
40. Awasthi S, Belse RB, Friedman HM. 24 April 2014. Better neutralization of HSV-1 than HSV-2 by antibody from subjects immunized with the GlaxoSmithKline gD2 vaccine. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu177.
41. Orhan G, Bayram A, Zer Y, Balci I. 2005. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43:140-143. http://dx.doi.org/10.1128/JCM.43.1.140-143.2005.
42. Cairns TM, Shaner MS, Zuo Y, Ponce-de-Leon M, Baribaud I, Eisenberg RJ, Cohen GH, Whitbeck JC. 2006. Epitope mapping of herpes simplex virus type 2 gH/gL defines distinct antigenic sites, including some associated with biological function. J. Virol. 80:2596-2608. http://dx.doi.org/10.1128/JVI.80.6.2596-2608.2006.
43. Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, Friedman HM. 2005. Herpes simplex virus type 1 glycoprotein E is required for axonal localization of capsid, tegument, and membrane glycoproteins. J. Virol. 79:13362-13372. http://dx.doi.org/10.1128/JVI.79.21.13362-13372.2005.
44. Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang ML, Warren T, Casper C, Corey L, Wald A. 2011. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J. Infect. Dis. 203:180-187. http://dx.doi.org/10.1093/infdis/jiq035.
45. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. 2011. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 305:1441-1449. http://dx.doi.org/10.1001/jama.2011.420.
46. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 99:1092-1097.
47. Harris MR, Coote PJ. 2010. Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int. J. Antimicrob. Agents 35:347-356. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.021.
48. Sprague ER, Wang C, Baker D, Bjorkman PJ. 2006. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 4:e148. http://dx.doi.org/10.1371/journal.pbio.0040148.
49. Ndjamen B, Farley AH, Lee T, Fraser SE, Bjorkman PJ. 2014. The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface. PLoS Pathog. 10:e1003961. http://dx.doi.org/10.1371/journal.ppat.1003961.
50. Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, Distefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM. 2014. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J. Virol. 88:2000-2010. http://dx.doi.org/10.1128/JVI.03163-13.
51. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB. 1984. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309:633-635. http://dx.doi.org/10.1038/309633a0.
52. Eisenberg RJ, Ponce de Leon M, Friedman HM, Fries LF, Frank MM, Hastings JC, Cohen GH. 1987. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb. Pathog. 3:423-435. http://dx.doi.org/10.1016/0882-4010(87)90012-X.
53. Seidel-Dugan C, Ponce de Leon M, Friedman HM, Fries LF, Frank MM, Cohen GH, Eisenberg RJ. 1988. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J. Virol. 62:4027-4036.
54. Weeks BS, Sundaresan P, Nagashunmugam T, Kang E, Friedman HM. 1997. The herpes simplex virus-1 glycoprotein E (gE) mediates IgG binding and cell-to-cell spread through distinct gE domains. Biochem. Biophys. Res. Commun. 235:31-35. http://dx.doi.org/10.1006/bbrc.1997.6720.
55. Saldanha CE, Lubinski J, Martin C, Nagashunmugam T, Wang L, van Der Keyl H, Tal-Singer R, Friedman HM. 2000. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease. J. Virol. 74:6712-6719. http://dx.doi.org/10.1128/JVI.74.15.6712-6719.2000.
56. Johansson PJ, Myhre EB, Blomberg J. 1985. Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulinG from different animal species. J. Virol. 56:489-494.
57. Huemer HP, Larcher C, van Drunen Littel-van den Hurk S, Babiuk LA. 1993. Species selective interaction of Alphaherpesvirinae with the "unspecific" immune system of the host. Arch. Virol. 130:353-364. http://dx.doi.org/10.1007/BF01309666.